1412, 2017

Atlas Molecular Pharma Receives European Medicines Agency (EMA) Orphan Designation for Congenital Erythropoietic Porphyria

DERIO, Spain.- Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), announced today a favourable report, as Orphan Medicinal Product, [...]

1403, 2017

ATLAS Molecular Pharma has been awarded with one of the prestigious NEOTEC grants (2016 call)

ATLAS Molecular Pharma succeeded with the competitive NEOTEC call (CDTI), obtaining a grant for a total amount of 213.000 EUR during the period 2017-2018. The NEOTEC Program aims to support the creation and consolidation of [...]

603, 2017

A possible pharmacological chaperone for congenital erythropoietic porphyria

The Chassys platform has been successfully applied for the identification of a series of putative pharmacological chaperones for the treatment of congenital erythropoietic porphyria. One of them is currently being validated, with most promising results. [...]

1209, 2016

Atlas Molecular Pharma will be attending BioSpain 2016 in Bilbao, September 28th – 30th

Join us at BioSpain 2016 in Bilbao, September 28th – 30th. If you want to find out more about what we do and are a potential Investor or Partner, please contact us through the BioSpain Partnering [...]

1209, 2016

CIC bioGUNE, CRB Inverbío, Kereon Partners and private investors create Atlas Molecular Pharma to discover new drugs for the treatment of Rare and Ultra-Rare diseases

The new company, Atlas Molecular Pharma, will further develop its proprietary technology to act as a “drug discovery engine” for the discovery and development of drugs called pharmacological chaperones, which act by restoring defective protein [...]

Go to Top